UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2021

Commission File Number: 001-39167

Molecular Data Inc.

11/F, Building 15, 2177 Shenkun Road

Minhang District, Shanghai 201106

People’s Republic of China
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒              Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Explanatory Note

On November 26, 2021, Molecular Data Inc. submitted herewith an interim balance sheet as of the end of its third quarter.

Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Interim Balance Sheet as of September 30, 2021

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Molecular Data Inc.
By :	/s/ Steven Foo
Name :	Steven Foo
Title :	Chief Executive Officer and Chief Financial Officer

Date: November 26, 2021

2

Exhibit 99.1

CONSOLIDATED STATEMENTS OF BALANCE SHEET

(Amounts in thousands of RMB and US$,

except for number of shares and per share data)

	As of December 31, 2020			As of September 30, 2021
	(RMB’000)			(RMB’000) unaudited			(USD’000)
Assets
Current assets:
Cash and cash equivalents		11,311			66,339			10,296
Restricted cash		277			—			—
Accounts receivable, net		5,963			6,211			964
Short-term investments		336,038			336,038			52,152
Unbilled receivables		51,825			56,842			8,822
Notes receivable		24,761			22,539			3,498
Inventories, net		2,821			5,784			898
Amounts due from related parties		1,144			7,178			1,114
Prepayments and other current assets		229,046			229,999			35,696
Total current assets		663,186			730,930			113,440
Non-current assets:
Long-term investment		353			3,753			582
Property and equipment, net		725			469			73
Intangible assets, net		536			372			58
Deferred assets & deferred tax assets		15,826			7,773			1,206
Right-of-use asset, net		4,195			2,796			434
Total non current assets		21,635			15,163			2,353
Total assets		684,821			746,093			115,793
Liabilities and Shareholders’ Equity
Current liabilities:
Short-term borrowings		33,749			16,149			2,506
Accounts payable		315,729			313,196			48,607
Deferred revenue		81,636			66,429			10,310
Accrued expenses and other liabilities		132,674			106,506			16,532
Convertible notes		16,096			39,453			6,123
Amounts due to related parties		111,186			119,531			18,551
Operating lease liabilities-current		1,536			1,393			216
Total current liabilities		692,606			662,657			102,845
Non-current liabilities:
Non-current portion of capital lease obligations		17,052			17,052			2,646
Non-current portion of lease liability		2,659			1,403			218
Contingency liability		341			341			53
Total non-current liabilities		20,052			18,796			2,917
Total liabilities		712,658			681,453			105,762
Redeemable noncontrolling interests		42			—			—
Shareholders’ equity/(deficit)
Ordinary shares		114			202			31
Additional paid-in capital		1,075,064			1,231,970			191,199
Accumulated other comprehensive loss		(21,192	)		(21,192	)		(3,289	)
Accumulated deficit		(1,081,914	)		(1,146,669	)		(177,961	)
Total shareholders’		(27,928	)		64,311			9,980
Non-controlling interest		49			329			51
TOTAL (DEFICIT)/EQUITY		(27,879	)		64,640			10,031
Total liabilities and shareholders’ (deficit)/ equity		684,821			746,093			115,793